Weiss Ratings Reaffirms “Sell (D-)” Rating for Zymeworks (NASDAQ:ZYME)

Zymeworks (NASDAQ:ZYME)‘s stock had its “sell (d-)” rating restated by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Zymeworks from a “hold” rating to a “buy” rating in a report on Sunday, August 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Zymeworks has a consensus rating of “Sell”.

Zymeworks Trading Up 1.4%

ZYME opened at $16.92 on Wednesday. Zymeworks has a 1-year low of $9.03 and a 1-year high of $17.70. The company has a market capitalization of $1.27 billion, a P/E ratio of -17.44 and a beta of 1.51. The firm has a fifty day moving average of $15.05.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($1.14) earnings per share for the quarter. The company had revenue of $4.40 million during the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.